Back to Research Feed

Life sciences · Observational Study

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

ClinicalTrials.gov · November 5, 2026

Why this matters to you Expert discussion

AI Summary

No summary has been generated for this record yet. What follows is drawn from its source metadata only.

What was studied

Observational Study.

Key findings

No findings were extractable from the material analysed.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

not graded

The material analysed did not support a judgement on this dimension.

Directness

not graded

The material analysed did not support a judgement on this dimension.

Consistency

not graded

The material analysed did not support a judgement on this dimension.

Risk of bias

not graded

The material analysed did not support a judgement on this dimension.

Sample adequacy

not graded

The material analysed did not support a judgement on this dimension.

This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.

What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07024862). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 103 participants (ACTUAL). Conditions: Metastatic Non-small Cell Lung Cancer. Interventions: BIOLOGICAL: nivolumab + ipilimumab. Primary outcome measures: Participant baseline socio-demographics , Baseline; Participant baseline clinical characteristics , Baseline; Participant treatment history , Baseline; Treatment start and stop dates , Up to 6-months; Reasons for 1L treatment selection , Day 1; Initial 1L NIC treatment dose received , Day 1; Type of chemotherapy received as part of NIC treatment , Day 1; Participant NIC treatment chemotherapy schedule , Day 1; Number of NIC treatment interruptions , Up to 6-months; Date(s) of NIC treatment interruptions , Up to 6-months; Reasons for NIC treatment interruptions , Up to 6-months; Length of NIC treatment delay/interruption , Up to 6-months; Reasons for NIC treatment discontinuation , Up to 6-months; Type of 2L treatment received , Up to 6-months; Reasons for not initiating 2L treatment , Up to 6-months; Start and stop dates of 2L treatment initiation , Up to 6-months. Brief summary: The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

Sign in to save Open original source